RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
复制标题
DOI:
10.1126/sciadv.abl9794
复制
发表时间:
2022-02-18
期刊:
影响因子:
13.6
通讯作者:
Jia L
中科院分区:
文献类型:
--
作者:
Miao C;Tsujino T;Takai T;Gui F;Tsutsumi T;Sztupinszki Z;Wang Z;Azuma H;Szallasi Z;Mouw KW;Zou L;Kibel AS;Jia L
Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and BRCA2, three closely located genes on chromosome 13q, are frequently deleted in prostate cancer individually or jointly. Loss of RNASEH2B confers cancer cells sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition due to impaired ribonucleotide excision repair and PARP trapping. When co-deleted with RB1, however, cells lose their sensitivity, in part, through E2F1-induced BRCA2 expression, thereby enhancing homologous recombination repair capacity. Nevertheless, loss of BRCA2 resensitizes RNASEH2B/RB1 co-deleted cells to PARP inhibition. Our results may explain some of the disparate clinical results from PARP inhibition due to interaction between multiple genomic alterations and support a comprehensive genomic test to determine who may benefit from PARP inhibition. Last, we show that ATR inhibition can disrupt E2F1-induced BRCA2 expression and overcome PARP inhibitor resistance caused by RB1 loss. PARP inhibitor sensitivity may depend on interaction between multiple genomic alterations.
登录
查看更多内容
影响因子:
7.3
作者:
Gao J;Aksoy BA;Dogrusoz U;Dresdner G;Gross B;Sumer SO;Sun Y;Jacobsen A;Sinha R;Larsson E;Cerami E;Sander C;Schultz N
通讯作者:
Schultz N
影响因子:
16
作者:
Buisson R;Boisvert JL;Benes CH;Zou L
通讯作者:
Zou L
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
--
作者:
Brookman-Amissah, Nicola;Nariculam, Joseph;Feneley, Mark R.
通讯作者:
Feneley, Mark R.
影响因子:
11.5
作者:
Chakraborty, Goutam;Armenia, Joshua;Kantoff, Philip W.
通讯作者:
Kantoff, Philip W.